

a. trans-ethnic GWAS meta-analysis



b. Caucasian GWAS meta-analysis





**Supplementary Figure 1: Quantile-quantile plot of single SNP test.** Quantile-quantile plots of P values in the (a) trans-ethnic GWAS meta-analysis; (b) Caucasian GWAS meta-analysis; (c) Chinese GWAS meta-analysis. Blue dots indicate whole genome wide statistic; red dots indicate SNPs outside the 41 known psoriasis risk loci; gray line represents expected under null hypothesis.



a. COG6



b. LOC144817

# STUDY (N)



c. RUNX1





**Supplementary Figure 2: The forest plot of four novel psoriasis risk SNPs.** (a) rs34394770 in COG6 gene; (b) rs9533962 in LOC144817 gene; (c) rs8128234 in RUNX1 gene; (d) rs28512356 in TP63 gene. In the left, it indicates each study. The Plots show the study-specific association estimates (odds ratios) and 95% confidence intervals for the discovery and second-stage studies presented as bars. The association estimate and confidence interval for the meta-analysis combining the discovery and second-stage results are shown as a blue diamond. Blank spaces indicate occasions in which a particular study was not able to provide results for a given SNP.



a. COG6

8



b. LOC144817



c. RUNX1



d. TP63



e. IL12B







### g. ERAP1/ERAP2 locus

Supplementary Figure 3: Regional association plot of four novel psoriasis risk loci and four independent secondary signals. The relative location of annotated genes and the direction of transcription are shown in the lower portion of the figure, and the chromosomal position is shown on the *x* axis. The blue line shows the recombination rate (estimated from HapMap data of CEU, CHB and Combined population) across the region (right *y* axis), and the left *y* axis shows the significance of the associations. The log10 *P* values from the log-additive genetic model for all SNPs in the region from the population meta analysis, trans-ethnic meta analysis or the conditional analysis. The square indicates the condition SNPs (these are the top or secondary SNPs); the circle labeled with rs IDs are reported psoriasis susceptibility SNPs, All circles and squares are color filled based on the heterogeneity results (such as  $I^2$ ) in the trans-ethnic meta analysis respectively. B, D, F are conditional association results of Caucasian, Chinese and combined GWAS meta-analysis respectively.



# a. B3GNT2



b. CARD14



c. CSMD1



d. DDX58



e. ELMO1







# g. EXOC2.IRF4



# h. FBXL19







j. IL13



k. IL23A.STAT2



l. ILF3.CARM1



m. KLF4



n. LCE region







q. PRDX5







s. PSMA6.NFKBIA





# t. PTRF.STAT3



u. REL



v. RNF114







w. RUNX3



x. SERPINB8



y. SLC45A1.TNFRSF9



# z. TAGAP



aa. TNFAIP3



# ab. TNIP1.ANXA6



# ac. TRAF3IP2



ad.TYK2



ae. UBE2L3



# af. ZC3H12C



# ag. ZNF816A

**Supplementary Figure 4: Regional association plot of 33 psoriasis risk loci.** The relative location of annotated genes and the direction of transcription are shown in the lower portion of the figure, and the chromosomal position is shown on the *x* axis. The blue line shows the recombination rate (estimated from HapMap data of CEU, CHB+JPT and Combined population) across the region (right *y* axis), and the left *y* axis shows the significance of the associations. The log10 *P* values from the log-additive genetic model for all SNPs in the region from the population meta analysis, trans-ethnic meta analysis or the conditional analysis. A, C and E are unconditional association results of Caucasian, Chinese and combined GWAS meta-analysis respectively. B, D, F are conditional association results of Caucasian, Chinese and combined GWAS meta-analysis respectively. The purple diamond indicates the *P* value for the reported SNP; the purple square indicates the condition SNPs (these are the top or secondary SNPs), their unconditional P values are shown; the purple circle labeled with rs IDs in purple font are psoriasis susceptibility SNPs with statistics presented in the tables, they are in the same LD block with reported or condition SNPs which are in black font rs IDs; grey font rs IDs are secondary SNPs which were not validated in our studies. All circles, squares and diamonds are color filled according to the level of heterogeneity among the 2 populations (such as  $I^2$ ).



a. In the Caucasian GWAS cohort







b. In the Chinese GWAS cohort

**Supplementary Figure 5: Regional association plot of** *HLA* **region.** The relative location of annotated genes and the direction of transcription are shown in the lower portion of the figure, and the chromosomal position is shown on the *x* axis. The green line shows the recombination rate (estimated from HapMap data of CEU, CHB+JPT and Combined population) across the region (right *y* axis), and the left *y* axis shows the significance of the associations. The log10 *P* values from the log-additive genetic model for all SNPs in the region from the population meta analysis or the conditional analysis. The horizontal red line indicates the genome-wide association significance criteria ( $P=5 \times 10^{-8}$ ), a Bonferroni corrected type I error rate based on the analysis in the whole genome common markers. A is unconditional association results of Caucasian, Chinese respectively. B, C, D, E are conditional association results of Caucasian, Chinese respectively. The Yellow diamond indicates the *P* value for the reported classical alleles; The blue circle indicates the reported SNPs in the paper; rs IDs in black or purple font are psoriasis susceptibility SNPs with statistics presented in the tables. (a) In the Caucasian GWAS cohort. (b) In the Chinese GWAS cohort.



Supplementary Figure 6: The correlation of odds ratios for the 30 SNPs in 27 shared loci between European and Chinese populations in this study. The risk effect size (odds ratios, OR) frequencies of 30 SNPs in 27 shared loci between two ancestries were significantly correlated (y = 0.39 + 0.69x,  $R^2 = 0.55$ ,  $P = 1.49 \times 10^{-6}$ ), *P*-value from linear regression of odd ratios between in European and in Chinese populations.



Supplementary Figure 7: The correlation of risk allele frequencies of 33 SNPs in 30 shared loci and between European and Chinese populations in this study. The three SNPs (rs13708, rs34394770 and rs2066807) with significant allele frequency heterogeneity were labelled in orange. The 30 SNPs in 27 shared loci were labelled in blue. The risk allele frequencies of 30 SNPs in 27 shared loci between two ancestries were significantly correlated (y = 0.14 + 0.66x,  $R^2 = 0.33$ , P = 0.0005), *P*-value from linear regression of risk alleles frequencies between in European and in Chinese populations.



Supplementary Figure 8: The distribution of median of standardized polygenic risk score (PRS) among Chinese and European in HGDP. The polygenic risk score (PRS) was calculated as described (Online Method). The *x*-axis indicates the populations. The *y*-axis indicates the median value of standardized PRS. The horizontal line indicates that the median value of standardized PRS is zero. The error bars show the 95% confidential interval. All median value of standardized PRS are connected by a line. Standardized genetic risk score is quite different among 52 HGDP populations with *P* of 1.15E-09 from Kruskal-Wallis test (non-parametric test). And the risk score is negatively correlated with longitude (*P*=3.23E-07), however not related to latitude of populations (*P*=0.053) from the spearman's rank correlation test. The Figure shows that the risk score is lower in Chinese than in European.

**Supplementary Table 1: Power calculation in Chinese sample.** The statistical power was as a function of disease allele frequency and genotype relation risk for the actual Chinese sample size used in our study. The power was calculated by QUANTO.

	Genotype Relation Risks(Log-Additive Model)									
Disease Allele Frequency	1.10	1.15	1.20	1.25	1.30	1.35	1.40			
0.10	0.18%	4.53%	30.62%	74.19%	96.21%	99.80%	99.99%			
0.20	1.87%	31.65%	85.90%	99.51%	99.99%	99.99%	99.99%			
0.30	5.37%	58.10%	97.46%	99.99%	99.99%	99.99%	99.99%			
0.40	8.61%	70.90%	99.15%	99.99%	99.99%	99.99%	99.99%			
0.50	9.66%	73.57%	99.33%	99.99%	99.99%	99.99%	99.99%			

SNP	chr	POS	r <sup>2</sup>	D'	Proxy SNPs	Ref	Alt	Enhancer histone marks	DNAse	Proteins bound
rs28512356	3	189615475	1	1	rs28512356	С	А	NHEK, HMEC	SAEC	GR,NRSF,POL2 B
rs28512356	3	189617088	0.98	1	rs71298526	GA	G	NHEK, HMEC	NHEK,HEEpi C,SAEC	
rs28512356	3	189617276	1	1	rs28688563	G	Т	NHEK, HMEC		
rs28512356	3	189623672	1	1	rs13081982	А	Т			
rs28512356	3	189627940	0.98	0.99	rs36006475	TA	Т	NHEK, HMEC, Huvec		
rs28512356	3	189637419	0.98	0.99	rs12485364	А	G			
rs28512356	3	189638198	0.83	0.99	rs13065424	G	А			
rs28512356	3	189638887	0.94	0.98	rs35822139	С	А			
rs34394770	13	40299842	0.95	0.99	rs35623045	ATAG	А			
rs34394770	13	40300328	0.89	0.99	rs9603603	Т	G			
rs34394770	13	40308307	0.97	0.99	rs9603605	Т	С			
rs34394770	13	40318819	0.99	1	rs9603608	А	С			
rs34394770	13	40319225	0.86	- 0.99	rs144565908	Т	А			
rs34394770	13	40319954	0.99	1	rs28635831	А	G			
rs34394770	13	40326282	0.98	1	rs9943	А	G			
rs34394770	13	40333369	1	1	rs34394770	Т	С			
rs34394770	13	40334852	0.99	1	rs9603612	С	G		GM18507,GM 19238	EBF1
rs34394770	13	40336770	0.98	1	rs60120504	AC	А			
rs34394770	13	40342557	0.99	1	rs12875311	G	A	ні	H1-hESC,H7- hESC	
rs34394770	13	40345356	0.99	1	rs7319041	G	А			
rs34394770	13	40345466	0.98	0.99	rs7320598	С	Т			
rs34394770	13	40350912	0.99	- 0.99	rs7993214	Т	С	5 cell types	56 cell types	NFKB,CFOS,P30 0
rs34394770	13	40351064	0.91	- 0.99	rs7986796	G	Т	5 cell types	HRGEC	
rs34394770	13	40351094	0.99	0.99	rs12876235	Т	G	5 cell types	HRGEC	
rs34394770	13	40351341	0.99	- 0.99	rs9532430	А	G	6 cell types	HAEpiC	MAFK
rs34394770	13	40352671	0.99	- 0.99	rs9532433	С	А	Huvec		
rs34394770	13	40353230	0.99	- 0.99	rs9548932	G	Т	Huvec, GM12878		

# Supplementary Table 2: The functional annotation of novel SNPs in ENCODE through HaploReg v2

rs34394770	13	40354200	0.99	0.99	rs12872801	С	Т	HSMM, Huvec	15 cell types	
rs34394770	13	40355913	0.99	- 0.99	rs9532434	Т	С			
rs34394770	13	40362229	0.97	0.99	rs8002731	А	С	HSMM, Huvec, H1		MAX
rs34394770	13	40368069	0.89	0.96	rs9603616	С	Т			
rs34394770	13	40368444	0.87	0.95	rs11618582	А	G			
rs34394770	13	40368601	0.89	0.96	rs9594366	С	Т			
rs9533962	13	45321621	0.92	0.97	rs7982911	G	А	HMEC, NHEK	AG09309	
rs9533962	13	45334194	1	1	rs9533962	С	Т	6 cell types	15 cell types	FOXA1
rs9533962	13	45342453	0.94	0.98	rs1415641	С	Т	4 cell types		NFKB
rs9533962	13	45342796	0.95	0.98	rs1415640	G	А	4 cell types		
rs9533962	13	45343590	0.95	0.98	rs9526002	А	G	HMEC, NHEK, GM12878	26 cell types	5 bound proteins
rs9533962	13	45355541	0.85	0.98	rs9533966	А	G		Fibrobl	
rs2853694	21	36470865	1	1	rs8128234	С	Т	K562		
rs2853694	2	163128824	1	1	rs3747517	Т	С			
rs2853694	5	158730368	1	1	rs4921464	А	G			SETDB1
rs2853694	5	158731548	1	1	rs1549922	G	А			
rs2853694	5	158733619	0.94	1	rs4921213	G	А			
rs2853694	5	158734517	1	1	rs11135058	Т	С		HeLa-S3	
rs2853694	5	158749088	1	1	rs2853694	G	Т			
rs4921493	5	158833535	0.93	0.98	rs12374547	G	А	GM12878		
rs4921493	5	158834367	0.93	0.98	rs60689680	G	Т			
rs4921493	5	158835178	0.87	0.99	rs200786876	TTTTTC	Т			
rs4921493	5	158835179	0.92	0.99	rs10556150	TTTTC	Т			
rs4921493	5	158836107	1	1	rs4921493	Т	С			
rs4921493	5	158836126	0.94	0.99	rs4921494	G	А			
rs4921493	5	158836581	0.94	1	rs12655757	С	Т	GM12878		
rs4921493	5	158839217	0.98	1	rs1422878	С	Т	GM12878		
rs4921493	5	158839512	0.99	1	rs1422877	А	G	H1, GM12878	21 cell types	NFKB,CEBPB,S TAT3
rs4921493	5	158839745	0.99	1	rs12651787	Т	С	GM12878, H1		EBF1
rs4921493	5	158841470	0.96	0.99	rs10476296	С	Т	GM12878	GM06990	
rs4921493	5	158843235	0.89	0.96	rs6863015	С	Α			
rs4921493	5	158843253	0.86	0.96	rs6888061	Т	С			
rs4921493	5	158844232	0.92	0.97	rs58368531	G	А	K562		
rs4921493	5	158846606	0.87	0.96	rs72802188	С	Т			CTCF
rs4921493	5	158848253	0.87	0.96	rs4921497	С	G			
rs4921493	5	158848433	0.86	0.95	rs4921498	G	А			
rs4921493	5	158849200	0.86	0.95	rs11743870	G	А			
					57	7				

rs4921493	5	158849636	0.86	0.95	rs10155584	G	А		5 cell types	
rs4921493	5	158849837	0.86	0.95	rs4921227	А	G			
rs4921493	5	158852944	0.85	0.95	rs7714401	Т	А	GM12878	FibroP	EBF1
rs4921493	5	158853941	0.85	0.95	rs2012830	А	Т	GM12878	GM12878,GM 12864,GM128 65	BATF
rs4921493	5	158856506	0.83	0.93	rs4921501	С	А			
rs4921493	5	158856513	0.83	0.94	rs4921228	С	А			

SNP: the reported novel SNP in our study; chr.: chromosome; Pos: physical position in HG19. r2 and D' indicate the linkage status between SNP and proxy SNPs.

GWAS SNP	Linked SNP	r <sup>2</sup>	D'	Tissue	P-value	Gene
rs34394770	rs4514547	0.7	0.88	Monocytes	9.50E-07	COG6
rs34394770	s9943	0.934	1	Monocytes	3.61E-05	COG6
rs34394770	rs12875311	0.934	1	Monocytes	3.36E-05	COG6
rs34394770	rs7993214	0.975	1	peripheral blood	7.11E-06	KIF18A

### Supplementary Table 3: The known eQTL effect at the four novel loci

GWAS SNP: the novel reported SNPs in our study; Linked SNP: the SNPs with high linkage disequilibrium with reported SNPs.  $r^2$  and D' indicate the linkage pair-wise status. P-value indicates the association between the SNP and the respective gene transcript.

						R	AF	Cauca	isian GWAS	Chin	ese GWAS	_	Combined All	
Analysis		rsid	Chr	BP.B37	RA	EUR	CHN	Р	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Po
Unconditional		rs7709212	5	158764177	Т	0.657	0.519	2.83E-20	1.37(1.31-1.44)	1.03E-11	1.4(1.31-1.5)	1.20E-30	1.38(1.33-1.44)	7.03E-01
		rs4921493	5	158836107	Т	0.641	0.642	3.89E-13	1.28(1.21-1.34)	6.89E-05	1.24(1.13-1.34)	2.22E-16	1.27(1.21-1.32)	6.27E-01
		rs2853694	5	158749088	G	0.495	0.323	2.98E-22	1.36(1.3-1.42)	2.12E-09	1.37(1.27-1.48)	8.61E-30	1.36(1.31-1.42)	8.87E-01
Conditioning	on	rs4921493	5	158836107	Т	0.641	0.642	2.70E-11	1.26(1.19-1.32)	4.66E-03	1.17(1.06-1.28)	6.80E-13	1.23(1.17-1.29)	2.78E-01
187709212		rs2853694	5	158749088	G	0.495	0.323	7.74E-08	1.23(1.16-1.31)	4.48E-03	1.19(1.07-1.31)	1.22E-09	1.22(1.16-1.28)	5.87E-01
Conditioning rs7709212 rs4021403	on &	ra2852604	5	158740088	G	0.405	0 222	1 01E 08	1 25(1 17 1 22)	5 24E 02	1 18(1 07 1 2)	3 70E 10	1 22(1 16 1 20)	4 76E 01
Multivariate		7700010	5	150764177	<u>т</u>	0.493	0.525	1.91E-08	1.23(1.17-1.32)	3.24E-03	1.18(1.07-1.3)	3.79E-10	1.23(1.10-1.29)	4.70E-01
analysis		rs//09212	5	158/641//	Г _	0.657	0.519	5.92E-05	1.19(1.09-1.29)	8.04E-05	1.26(1.12-1.42)	3.35E-08	1.21(1.13-1.3)	5.38E-01
		rs4921493	5	158836107	Т	0.641	0.642	8.14E-12	1.26(1.18-1.35)	6.19E-03	1.16(1.04-1.3)	3.52E-13	1.23(1.17-1.31)	3.92E-01
		rs2853694	5	158749088	G	0.495	0.323	1.93E-08	1.25(1.15-1.34)	3.82E-03	1.19(1.06-1.34)	4.24E-10	1.23(1.15-1.31)	2.12E-01

Supplementary Table 4a: Conditional association results of *IL12B* gene region

Chr: chromosome; BP.B37: position based on NCBI build 37; RA: risk/non-risk alleles; RAF: risk allele's frequencies; EUR: European samples; CHN: Chinese samples; *P*: association *P* values in the meta, trans ethnic meta analysis or the conditional study (alleles dosages in GWAS studies); OR: odds ratio; 95% CI: 95% confidence interval; p<sub>0</sub>: heterogeneity P values.

There were three independent loci identified: rs7709212, rs4921493, rs2853694.

Supplementary Table 4b: The	pairwise linkage dised	uilibrium among the	three SNPs in <i>IL12B</i> locus

	rs492	1493	rs28	53694
SNP	CEU	JPT+CHB	CEU	JPT+CHB
rs7709212	r <sup>2</sup> =0.019,D'=0.206	r <sup>2</sup> =0.033,D'=0.209	r <sup>2</sup> =0.499,D'=0.854	r <sup>2</sup> =0.269,D'=0.892
rs2853694	r <sup>2</sup> =0.024,D'=0.19	r <sup>2</sup> =0.008,D'=0.103	/	/

\* The Linkage disequilibrium was calculated based on the samples from CEU population and JPT, CHB populations in HapMap.

				European GWAS				Chines	e GWAS		Combined			
Haplotype	rs2853694	rs7709212	rs4921493	Freq_contrl	Freq_case	OR (95% CI)	Р	Freq_contrl	Freq_case	OR (95% CI)	Р	OR (95% CI)	Р	PQ
1	Т	Т	Т	15.44%	15.37%	-	-	16.51%	20.16%	-	-	-	-	-
2	G	С	С	1.69%	1.33%	0.83(0.63-1.08)	1.72E-01	0.58%	0.81%	1.56(0.88-2.76)	1.28E-01	0.93(0.73-1.2)	5.54E-01	5.02E-02
3	G	С	Т	0.92%	1.10%	1.15(0.84-1.57)	3.91E-01	1.79%	1.58%	0.82(0.55-1.22)	3.22E-01	1.01(0.79-1.3)	9.47E-01	1.91E-01
4	G	Т	С	14.36%	14.76%	1.05(0.94-1.17)	4.08E-01	4.58%	4.72%	0.88(0.68-1.14)	3.30E-01	1.02(0.92-1.1)	7.14E-01	2.21E-01
5	G	Т	Т	32.66%	39.80%	1.23(1.12-1.35)	2.04E-05	25.21%	32.49%	1.17(1.01-1.36)	3.13E-02	1.21(1.12-1.3)	2.07E-06	6.08E-01
6	Т	С	С	16.10%	11.71%	0.73(0.65-0.81)	5.64E-08	24.00%	18.35%	0.7(0.6-0.82)	1.19E-05	0.72(0.65-0.8)	3.21E-12	7.39E-01
7	Т	С	Т	16.01%	14.00%	0.88(0.78-0.98)	2.28E-02	21.76%	18.18%	0.78(0.67-0.92)	2.85E-03	0.85(0.77-0.9)	3.40E-04	2.64E-01
8	Т	Т	С	2.83%	1.92%	0.68(0.55-0.85)	7.08E-04	5.57%	6.30%	0.92(0.73-1.17)	5.03E-01	0.79(0.67-0.9)	3.56E-03	6.43E-02

# Supplementary Table 4c: Haplotypic association for markers in *IL12B* locus with the risk of psoriasis

Haplotype 1 was set as reference. Freq\_contrl/Freq\_cases : the haplotype frequency in controls/cases; P: the association P values for each haplotype in the specified population ; OR: odds ratio; 95% CI: 95% confidence interval;  $P_0$ : heterogeneity P values.

					A	RF	Combined European		Comb	oined Chinese	Combined All		
Analysis	rsid	Chr	BP.B37	RA	EUR	CHN	Р	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	p <sub>Q</sub>
Unconditional	rs1990760	2	163124051	Т	0.614	0.188	3.21E-13	1.2(1.14-1.26)	6.33E-01	1.02(0.95-1.08)	1.92E-09	1.12(1.08-1.17)	3.29E-05
	rs3747517	2	163128824	С	0.726	0.311	1.53E-01	1.04(0.99-1.1)	2.96E-04	0.91(0.86-0.96)	1.12E-01	0.97(0.94-1.01)	3.81E-04
	rs2111485	2	163110536	G	0.611	0.174	1.02E-07	1.19(1.12-1.27)	1.59E-01	1.1(0.96-1.25)	7.20E-08	1.17(1.11-1.24)	2.52E-01
	rs17716942	2	163260691	Т	0.868	NA	7.80E-04	1.18(1.07-1.3)	NA	NA	7.80E-04	1.18(1.07-1.3)	1.00E+00
Conditioning on rs1990760	rs3747517	2	163128824	С	0.726	0.311	2.87E-11	0.75(0.69-0.81)	5.16E-09	0.8(0.74-0.86)	1.52E-18	0.77(0.73-0.82)	3.26E-01
	rs2111485	2	163110536	G	0.611	0.174	5.09E-01	1.09(0.84-1.42)	2.12E-01	0.81(0.57-1.13)	8.08E-01	0.97(0.79-1.2)	1.65E-01
	rs17716942	2	163260691	Т	0.868	NA	1.62E-01	1.08(0.97-1.2)	NA	NA	1.62E-01	1.08(0.97-1.2)	1.00E+00
Multivariate analysis	rs1990760	2	163124051	Т	0.614	0.188	9.45E-23	1.48(1.37-1.6)	2.85E-06	1.24(1.13-1.35)	1.39E-25	1.37(1.29-1.45)	1.99E-02
	rs3747517	2	163128824	С	0.726	0.311	2.69E-11	0.75(0.69-0.81)	4.23E-09	0.80(0.74-0.86)	1.17E-18	0.77(0.73-0.82)	6.52E-01

Supplementary Table 5a: Conditional association results of IFIH1 gene region

Chr: chromosome; BP.B37: position based on NCBI build 37; RA: risk/non-risk alleles; RAF: risk allele's frequencies; EUR: European samples; CHN: Chinese samples; P: association P values in the meta, trans-ethnic meta analysis or the conditional study (alleles dosages in GWAS studies); OR: odds ratio; 95% CI: 95% confidence interval; p<sub>0</sub>: heterogeneity P values.

There were two independent loci identified in our study (Caucasian): rs1990760, rs3747517. The two reported independent loci: rs17716942 and rs2111485, published by Lam et al (Nature Genetics, Nov 2012) are tagged by rs1990760.

				Combined	European			Combine	ed Chinese		Combined All			
Haplotype	rs1990760	rs3747517	Freq_contrl	Freq_case	OR (95% CI)	Р	Freq_contrl	Freq_case	OR (95% CI)	Р	OR (95% CI)	Р	pq	
1	С	Т	27.69%	27.13%	-	-	68.22%	69.94%	-	-	-	-	-	
2	С	С	12.79%	9.27%	0.7(0.64-0.78)	4.66E-12	13.05%	10.91%	0.81(0.75-0.87)	2.85E-08	0.77(0.72-0.8)	7.90E-18	3.26E-02	
3	Т	С	59.50%	63.58%	1.04(0.97-1.1)	2.85E-01	18.73%	19.12%	0.98(0.92-1.04)	4.76E-01	1.01(0.96-1.1)	8.18E-01	2.06E-01	
4	Т	Т	0.02%	0.01%	0.59(0.04-8)	6.92E-01	0.00%	0.03%	NA	8.60E-01	0.59(0.04-8)	6.95E-01	8.53E-01	

### Supplementary Table 5b: Haplotypic association for markers in *IFIH1* locus with the risk of psoriasis

Haplotype 1 was set as reference. Freq\_contrl/Freq\_cases: the haplotype frequency in controls/cases; *P*: association *P* values for each haplotype in specified population; OR: odds ratio; 95% CI: 95% confidence interval;  $p_Q$ : heterogeneity *P* values.

Supplementary	Table 5c: The	pairwise linkage	e disequilibrium ar	mong the three	SNPs in <i>IFIH1</i> locus
Supplementary	I dole c c l I lle	Part 11 100 minug	and a sequence i and a	mong the thirde	

	rs2111	485	rs177	16942	rs3747517		
SNP	CEU	JPT+CHB	CEU	JPT+CHB	CEU	JPT+CHB	
rs1990760	r <sup>2</sup> = 0.826, D' = 0.925	$r^2 = 0.78$ , D' = 1.00	$r^2 = 0.20, D' = 0.85$	r <sup>2</sup> = 0.001, D' = 1.00	r <sup>2</sup> =0.409, D'=1.00	r <sup>2</sup> =0.453,D'=1.00	

\* The Linkage disequilibrium was calculated based on the samples from CEU population and JPT, CHB populations in HapMap.

					RAF		Combined European		Combined Chinese		Combined All		
Analysis	rsid	Chr	BP.B37	RA	EUR	CHN	Р	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	$\mathbf{p}_{\mathrm{Q}}$
Unconditional	rs30376	5	96120259	С	0.286	0.503	5.31E-05	1.12(1.06-1.18)	1.84E-09	1.16(1.11-1.22)	7.23E-13	1.14(1.1-1.18)	3.21E-01
	rs2910686	5	96252589	С	0.424	0.398	7.24E-03	1.07(1.02-1.13)	6.65E-05	0.9(0.86-0.95)	3.15E-01	0.98(0.95-1.02)	2.57E-06
Conditioning on rs30376	rs2910686	5	96252589	С	0.424	0.397	1.21E-06	1.15(1.09-1.22)	6.74E-01	0.99(0.93-1.05)	1.37E-03	1.07(1.03-1.12)	3.43E-04

Supplementary Table 6: Conditional association results of ERAP1/ERAP2 gene region

Chr: chromosome; BP.B37: position based on NCBI build 37; RA: risk/non-risk alleles; RAF: risk allele's frequencies; EUR: European samples; CHN: Chinese samples; *P*: association P values in the meta, trans ethnic meta analysis or the conditional study (alleles dosages in GWAS studies); OR: odds ratio; 95% CI: 95% confidence interval; p<sub>0</sub>: heterogeneity P values.

There were two independent signal identified: rs30376 (*ERAP1*, tagged rs27432), rs2910686 (*ERAP2*, reported by Lam et al (Nature Genetics, Nov 2012)). The secondary locus is showing association evidence in Caucasian only.

# Supplementary Table 7: The association results of *HLA* region in Caucasian and Chinese samples

a	<b>T</b> 7 • 4	Caucasians			Chinese			
Condition on	variant	MAF all	OR (95% CI)	Р	MAF all	OR (95% CI)	Р	
None	HLA-C*0602	14.80%	4.00 (3.62-4.41)	3.05 x 10 <sup>-167</sup>	13.80%	11.3(9.05-14.11)	2.09 x 10 <sup>-101</sup>	
HLA-C*0602	HLA-A*0207	0	Absent	Absent	10.70%	2.99 (2.54-3.51)	5.30 x 10 <sup>-40</sup>	
HLA-C*0602 + HLA-A*0207	AA_B_67	8 to 42%	omnibus	4.31 x 10 <sup>-25</sup>	8 to 54%	omnibus	8.96 x 10 <sup>-25</sup>	
HLA-C*0602 + HLA-A*0207 + AA_B_67	HLA-A*0201	31.40%	1.26 (1.17-1.36)	3.62 x 10 <sup>-10</sup>	13.10%	1.23 (1.03-1.49)	0.026	
	AA_A_114	2 to 43%	omnibus	2.46 x 10 <sup>-5</sup>	8 to 54%	omnibus	6.04 x 10 <sup>-13</sup>	
HLA-C*0602 + HLA-A*0207 + AA_B_67 + 1 variant	rs9265656	14.30%	1.64 (1.39-1.93)	5.27 x 10 <sup>-9</sup>	-	not imputed	not imputed	
	HLA-B*07	11.70%	0.60 (0.47-0.75)	1.13 x 10 <sup>-5</sup>	1.20%	0.70 (0.40-1.21)	0.2	
	rs3131857	39.40%	1.02 (0.95-1.10)	0.56	22.60%	1.63 (1.36 -1.95)	9.76 x 10 <sup>-8</sup>	
	AA_A_144	20%	0.95 (0.86-1.04)	0.23	22.60%	0.65 (0.55-0.78)	1.55 x 10 <sup>-6</sup>	

MAF: minor allele frequency; OR: odds ratio; 95% CI: 95% confidence interval. *P*: association P values in the meta, trans ethnic meta analysis or the conditional study.

			Combined European			Combined Chinese				Co	Combined All		
Haplotype	rs2295359	rs12564022	Freq_contrl	Freq_case	OR (95% CI)	Р	Freq_contrl	Freq_case	OR (95% CI)	Р	OR (95% CI)	Р	pq
1	А	С	33.06%	32.93%	-	-	31.75%	34.98%	-	-	-	-	-
2	А	Т	1.26%	2.16%	1.53(1.28-1.83)	4.51E-06	2.58%	2.53%	0.87(0.74-1.01)	7.27E-02	1.1(0.98-1.24)	1.03E-01	1.09E-08
3	G	С	38.88%	35.22%	0.88(0.84-0.93)	6.31E-06	10.33%	8.78%	0.74(0.68-0.81)	7.04E-11	0.84(0.81-0.88)	4.70E-13	7.64E-03
4	G	Т	26.80%	29.69%	1.06(1-1.13)	3.83E-02	55.33%	53.71%	0.88(0.84-0.93)	5.86E-06	0.96(0.93-1)	5.44E-02	2.35E-05
4	G	Т	26.80%	29.69%	-	-	55.33%	53.71%	-	-	-	-	-
2	А	Т	1.26%	2.16%	0.88(0.73-1.05)	1.64E-01	2.58%	2.53%	0.97(0.83-1.14)	7.35E-01	0.93(0.83-1.05)	2.48E-01	2.29E-06
3	G	С	38.88%	35.22%	0.83(0.77-0.9)	1.94E-06	10.33%	8.78%	0.84(0.77-0.91)	5.01E-05	0.83(0.79-0.88)	4.11E-10	6.84E-05
1	А	С	33.06%	32.93%	0.91(0.84-0.99)	2.46E-02	31.75%	34.98%	1.13(1.07-1.19)	5.86E-06	1.06(1.01-1.11)	1.24E-02	8.08E-08

Supplementary Ta	able 8: Haplotypic	association for ma	rkers in <i>IL23R</i> loo	cus with the risk	of psoriasis
11 5	1 1 1				

Haplotype 1 was set as reference. Freq\_contrl/Freq\_cases : the haplotype frequency in controls/cases; P: association P values for each haplotype in the specified population ; OR: odds ratio; 95% CI: 95% confidence interval;  $p_Q$ : heterogeneity P values.

Gene	Catalog	Term	P-value	Annotated
TP63	1	epidermis development	1.79E-31	YES
TP63	1	skin development	5.63E-20	YES
RUNX1	1	negative regulation of alpha-beta T cell differentiation	2.35E-07	NO
RUNX1	1	negative regulation of immune effector process	2.00E-06	NO
RUNX1	1	regulation of epidermis development	2.61E-06	NO

Supplementary Table 9: Results of gene function prediction analysis in 80000 gene expression profiles of identified genes

Phenotypic annotations are obtained from the Mouse Genetics Initiative database

(www.informatics.jax.org). Table lists only genes and phenotypic annotations directly related to skin or epidermis development or immunological regulation. P-values refer to the correlation between the Gene principal component profile and the reconstituted phenotypic annotation principal component profile, uncorrected for multiple testing; all reported terms meet False Discovery Rate < 0.05. The Annotated column indicates if the gene has previously been linked to a specific mouse phenotype (Y) or not (N). Results are sorted alphabetically by gene name. The catalog means category of pathway. Pathway terms originate from 6 databases: 1. Gene Ontology Biological Processes; 2. Gene Ontology Cellular Component; 3. Gene Ontology Molecular Function; 4. KEGG; 5. BioCarta; and 6. Reactome.

Tissue	No of samples	AUC	P-value
Skin	545	0.89	5 x 10 <sup>-216</sup>
Keratinocytes	48	0.85	2 x 10 <sup>-17</sup>
Epithelium	183	0.78	9 x 10 <sup>-39</sup>

### Supplementary Table 10: The correlation between TP63 gene and tissue expression

Results of the tissue, organ and tissue type specific expression analysis in 80,000 gene expression profiles. The expression profiles were annotation into tissues, organs, or cell types using the MeSH database (http://www.nlm.nih.gov/mesh/). Table lists only genes in which show high expression in skin or specific skin relevant cells. Sample count specifies the number of expression profiles annotated with given annotation. AUC (area under the curve) gives the estimate how much of the variation on given gene expression profile is explained by a given tissue, organ or tissue type. *P*-values refer to enriched expression for a given gene in specific tissue, organ or tissue type compared to all other annotation terms.

# Supplementary Table 11: The GO Enrichment Analysis of Implicated genes.

Term	Genes	Р
GO:0002682:regulation of immune system process	DDX58, ERAP1, IRF4,IL12B, IL13, IL28RA, NOS2,NFKBIA, <u>RUNX1</u> , ETS1	4.14E-06
GO:0050776:regulation of immune response	DDX58, ERAP1, IRF4, IL12B, IL13, IL28RA, NOS2, NFKBIA	8.96E-06
GO:0048518:positive regulation of biological process	DDX58, KLF4, TRAF3IP2, CARD14, ERAP1,IRF4,IL12B,IL13, ILF3, NOS2, NFKBIA,PSMA6, <u>RUNX1</u> , RUNX3, STAT3, TNFRSF9, <u>TP63</u> , ETS1,REL, ZMIZ1	1.14E-05
GO:0002376:immune system process	DDX58, TRAF3IP2, ERAP1, ERAP2, IFIH1, IRF4,IL12B, IL13, IL23R, IL23A, NOS2, NFKBIA, <u>RUNX1,</u> ETS1	1.49E-05
GO:0010604:positive regulation of macromolecule metabolic process	KLF4, CARD14,IRF4,IL12B, ILF3, NFKBIA, PSMA6, <u>RUNX1</u> , STAT3, <u>TP63</u> , ETS1, REL, ZMIZ1	1.68E-05
GO:0031325:positive regulation of cellular metabolic process	KLF4, CARD14,IRF4,IL12B, ILF3, NFKBIA, PSMA6, <u>RUNX1,</u> STAT3, <u>TP63</u> , ETS1, REL, ZMIZ1	2.19E-05
GO:0045893:positive regulation of transcription, DNA-dependent	KLF4, IRF4, ILF3, NFKBIA, <u>RUNX1,</u> STAT3, <u>TP63,</u> ETS1,REL, ZMIZ1	2.31E-05
GO:0051254:positive regulation of RNA metabolic process	KLF4, IRF4, ILF3, NFKBIA, <u>RUNX1,</u> STAT3, <u>TP63,</u> ETS1,REL, ZMIZ1	2.47E-05
GO:0009893:positive regulation of metabolic process	KLF4, CARD14, IRF4, IL12B, ILF3, NFKBIA, PSMA6, <u>RUNX1,</u> STAT3, <u>TP63,</u> ETS1, REL, ZMIZ1	3.44E-05
GO:0009607:response to biotic stimulus	DDX58, ERAP1, IFIH1, IL23A, NOS2, NFKBIA, STAT2, SOCS1, TP63	3.46E-05
GO:0051707:response to other organism	DDX58, ERAP1, IFIH1, IL23A, NOS2, NFKBIA, STAT2, SOCS1	4.47E-05
GO:0010557:positive regulation of macromolecule biosynthetic process	KLF4, IRF4,IL12B, ILF3, NFKBIA, <u>RUNX1,</u> STAT3, <u>TP63,</u> ETS1, REL, ZMIZ1	4.65E-05
GO:0031328:positive regulation of cellular biosynthetic process	KLF4, IRF4,IL12B, ILF3, NFKBIA, <u>RUNX1</u> , STAT3, <u>TP63</u> , ETS1, REL, ZMIZ1	6.86E-05
GO:0006955:immune response	DDX58, TRAF3IP2, ERAP1, ERAP2, IFIH1, IL12B, IL13, IL23R, IL23A, NOS2, ETS1	7.29E-05
GO:0009891:positive regulation of biosynthetic process	KLF4, IRF4, IL12B, ILF3, NFKBIA, <u>RUNX1,</u> STAT3, <u>TP63,</u> ETS1, REL, ZMIZ1	7.75E-05
GO:0045941:positive regulation of transcription	KLF4, IRF4, ILF3, NFKBIA, RUNX1, STAT3, TP63, ETS1,REL, ZMIZ1	8.52E-05

The column of Genes lists the genes in each GO term from the input genes. The novel genes in our study were underlined and bonded. The *P* indicates the Fisher's exact test result.